Literature DB >> 32942037

The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle.

Guillermo Carvajal Alegria1, Sara Boukhlal2, Divi Cornec3, Valérie Devauchelle-Pensec3.   

Abstract

Polymyalgia rheumatica (PMR) is a frequent rheumatic condition among people over 50 years of age. Despite its frequent association with giant cell arteritis (GCA), PMR can be isolated. Its pathophysiology is poorly understood. Nevertheless, many studies are ongoing; 98 studies are currently referenced in ClinicalTrials.org involving several conventional and targeted therapies. In this review, we synthetize the current knowledge about PMR pathophysiology according to genetic and immunogenetic, immunologic, antibody and aging data. Immunogenetic data are mainly related to the HLA system and the association between the HLA-DRB1 and PMR. Few studies are also about immunogenetics of proinflammatory interleukins (i.e. IL-6). The decrease of CD8+Tcells and the strong increase of IL-6 where the main elements of PMR's pathophysiology until the recent years. The disturbance of B cell homeostasis, the search for IL-6 secretion by the innate immune system, the role of aging, are new elements revealed by recent studies. Aging might be a key element to consider as PMR occurs in patients over 50 years of age. Aging may act by the increased susceptibility to infections, by immunological modifications or hormonal disturbances. The role of the cellular infiltration around the joints remains a crucial question. Only a handful of studies described this infiltration. Finally, this review reveals the gaps in available data and suggests new leads and in-depth studies for further research on PMR pathophysiology.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aging; B cell; HLA-DR; Interleukin-6; Polymyalgia rheumatica; T cell

Year:  2020        PMID: 32942037     DOI: 10.1016/j.autrev.2020.102670

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  6 in total

Review 1.  Polymyalgia Rheumatica.

Authors:  Miriam Giovanna Colombo; Anna-Jasmin Wetzel; Hannah Haumann; Simon Dally; Gudula Kirtschig; Stefanie Joos
Journal:  Dtsch Arztebl Int       Date:  2022-06-17       Impact factor: 8.251

Review 2.  Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following COVID-19 vaccines: working notes from a narrative review of published literature.

Authors:  Ciro Manzo; Alberto Castagna; Marco Isetta
Journal:  Reumatologia       Date:  2022-05-18

3.  Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats.

Authors:  Qingmei Xu; Xin Tan; Wei Xian; Jiayi Geng; Haoyu Li; Bi Tang; Heng Zhang; Hongju Wang; Qin Gao; Pinfang Kang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-09-07       Impact factor: 3.168

4.  Polymyalgia Rheumatica After ChAdOx1 nCov-19 Vaccine: A Case Report.

Authors:  Carolina Lourenço; Adriana Pascoal; António Paiva; Inês Campos; José Pagaimo
Journal:  Cureus       Date:  2022-05-26

5.  Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica.

Authors:  Rosanne D Reitsema; William F Jiemy; Lieske Wekema; Annemieke M H Boots; Peter Heeringa; Minke G Huitema; Wayel H Abdulahad; Yannick van Sleen; Maria Sandovici; Caroline Roozendaal; Arjan Diepstra; Thomas Kwee; Bhaskar Dasgupta; Elisabeth Brouwer; Kornelis S M van der Geest
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

6.  The Role of Tumor Necrosis Factor Alpha Antagonists (Anti TNF-α) in Personalized Treatment of Patients with Isolated Polymyalgia Rheumatica (PMR): Past and Possible Future Scenarios.

Authors:  Ciro Manzo; Elvis Hysa; Alberto Castagna; Marco Isetta
Journal:  J Pers Med       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.